Acute Respiratory Distress Syndrome
Rapid failure of the lungs caused by severe inflammation, causing them to fill with fluid and requiring a mechanical ventilator to survive.
Emergency Management: Refractory hypoxemia crashing into cardiac arrest. Requires immediate 100% FiO2, checking tube placement, and considering emergent proning or ECMO.
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening form of severe hypoxic respiratory failure characterized by rapid onset of diffuse inflammatory lung injury. This injury leads to increased pulmonary vascular permeability, resulting in non-cardiogenic pulmonary edema and a profound loss of aerated lung tissue. It manifests clinically as severe hypoxemia refractory to supplemental oxygen and bilateral radiographic opacities.
Detailed Overview
ARDS is not a primary disease but rather a devastating clinical syndrome triggered by massive systemic or local inflammation (e.g., severe sepsis, pneumonia, massive trauma, or aspiration). The inflammatory cascade damages the alveolar-capillary barrier, causing protein-rich fluid to flood the alveoli. This inactivates surfactant, leading to widespread alveolar collapse, massive intrapulmonary right-to-left shunting, and 'stiff' lungs (decreased compliance). Management hinges on treating the underlying cause and providing mechanical ventilation using lung-protective strategies (low tidal volumes) to prevent ventilator-induced lung injury (VILI).
Epidemiology & Demographics
Accounts for 10% of all ICU admissions and 24% of mechanically ventilated patients. High mortality rate ranging from 35% to 46% depending on severity.
Etiological Mechanism
Direct lung injury: Pneumonia (bacterial/viral, e.g., COVID-19), aspiration of gastric contents, pulmonary contusion, near-drowning. Indirect lung injury: Sepsis (most common), severe trauma/shock, acute pancreatitis, massive transfusion (TRALI).
Primary Causes
An overwhelming systemic or pulmonary inflammatory response that catastrophically damages the alveolar-capillary membrane.
Pathologically described as Diffuse Alveolar Damage (DAD). It progresses through three phases. 1. Exudative Phase (Days 1-7): Insult triggers macrophage release of TNF, IL-1, and IL-8, recruiting neutrophils. Neutrophils release ROS and proteases, destroying the alveolar-capillary membrane (Type I pneumocytes and endothelial cells). Protein-rich fluid floods alveoli. Hyaline membranes form. 2. Proliferative Phase (Days 7-21): Type II pneumocytes proliferate to repair the epithelium. Fibroblasts begin to organize the exudate. 3. Fibrotic Phase (Weeks to Months): In some patients, excessive collagen deposition causes extensive pulmonary fibrosis, permanently destroying lung architecture and compliance.
Diagnostic Criteria & Guidelines
Diagnosed by the Berlin Definition: 1. Acute onset within 1 week of known clinical insult. 2. Bilateral opacities on chest imaging not fully explained by effusions/atelectasis. 3. Respiratory failure not fully explained by cardiac failure/fluid overload (objective assessment like echo needed if no clear ARDS risk factor). 4. Hypoxemia defined by PaO2/FiO2 ratio ≤ 300 mmHg with a minimum PEEP of 5 cm H2O.
Intubation and mechanical ventilation using Lung-Protective Strategy: Low tidal volumes (4-6 mL/kg of Ideal Body Weight) to prevent volutrauma, and adequate PEEP (e.g., 10-20 cm H2O) to keep alveoli open (prevent atelectrauma). Target plateau pressures < 30 cm H2O.
Second-Line & Adjunctive Therapy
For refractory hypoxemia (Severe ARDS): Prone positioning (placing patient on stomach for 16 hours/day) to improve V/Q matching. Neuromuscular blockade (cisatracurium). ECMO (Extracorporeal Membrane Oxygenation) as a salvage therapy.
Surgical & Procedural Management
None specific for ARDS, though surgical source control (e.g., laparotomy for perforated bowel) is critical if sepsis is the driver.
Patient Counseling & Advice
Counsel family regarding the high mortality rate and the fact that recovery (weaning off the ventilator) takes weeks. Survivors often suffer from 'Post-Intensive Care Syndrome' (PICS) including PTSD and cognitive deficits.
Follow-Up & Monitoring Schedule
Continuous intensive care monitoring. Daily assessment of ventilator mechanics (plateau pressure, driving pressure, compliance) and blood gases.
Preventive Strategies
Careful fluid management (conservative strategy) in ICU patients. Rapid identification and treatment of sepsis.
Mortality is 35-45%. Most survivors regain nearly normal lung function over 6-12 months, though some are left with restrictive lung disease. Muscle weakness and cognitive decline are major long-term issues.